Novel m1 muscarinic agonists in treatment and delaying the progression of Alzheimer's disease: an unifying hypothesis.
M1 selective agonists from the AF series (e.g. AF102B, AF150(S)), via m1 muscarinic receptors, activate distinct signal transductions, enhance amyloid precursors proteins secretion from transfected cells and primary cell cultures, show neurotrophic effects and are beneficial in a variety of animal models for Alzheimer's disease. Such m1 agonists may be effective in the treatment and therapy of Alzheimer's disease.
Fisher
A
A
Israel Institute for Biological Research, Ness-Ziona, Israel.
Brandeis
R
R
Haring
R
R
Eshhar
N
N
Heldman
E
E
Karton
Y
Y
Eisenberg
O
O
Meshulam
H
H
Marciano
D
D
Bar-Ner
N
N
Pittel
Z
Z
D000544:Alzheimer Disease / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology*; D016564:Amyloid beta-Protein Precursor / Q000378:metabolism; D000818:Animals; D018450:Disease Progression; D006801:Humans; D008959:Models, Neurological; D018721:Muscarinic Agonists / Q000627:therapeutic use*
D016564:Amyloid beta-Protein Precursor; D018721:Muscarinic Agonists